{"id":"NCT01523587","sponsor":"Boehringer Ingelheim","briefTitle":"LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy","officialTitle":"LUX-Lung 8: A Randomized, Open-label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second-line Therapy Following First-line Platinum-based Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-03-05","primaryCompletion":"2013-10-21","completion":"2017-12-27","firstPosted":"2012-02-01","resultsPosted":"2014-11-21","lastUpdate":"2019-02-15"},"enrollment":795,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"afatinib","otherNames":[]},{"type":"DRUG","name":"erlotinib","otherNames":[]}],"arms":[{"label":"Afatinib","type":"EXPERIMENTAL"},{"label":"Erlotinib","type":"ACTIVE_COMPARATOR"}],"summary":"This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.","primaryOutcome":{"measure":"Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1","timeFrame":"First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).","effectByArm":[{"arm":"Afatinib","deltaMin":2.63,"sd":null},{"arm":"Erlotinib","deltaMin":1.94,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0103"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":192,"countries":["United States","Argentina","Austria","Canada","Chile","China","Denmark","France","Germany","Greece","Hungary","India","Ireland","Italy","Mexico","Netherlands","Portugal","Singapore","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["30573970","29902295","28577938","26156651"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":174,"n":392},"commonTop":["Diarrhoea","Rash","Decreased appetite","Nausea","Dyspnoea"]}}